Randall Bateman with DIAN-Tu participant (IMAGE)

WashU Medicine

Randall Bateman with DIAN-Tu participant

Caption

Trial participant Rachel Habiger meets in 2018 with Randall J. Bateman, MD, the director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University School of Medicine in St. Louis. The DIAN-TU has announced that it will be targeting two key Alzheimer’s proteins — amyloid and tau — as part of its Tau Next Generation Alzheimer’s prevention trial.

Credit

Matt Miller/Washington University

Usage Restrictions

This image is to be used in accordance with the mission, policies and guidelines of Washington University in St. Louis. Visit https://wustl.edu/about/compliance-policies/media-policies/multimedia-use/ for more information.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.